# Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

> **NCT05189093** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hangzhou Hanx Biopharmaceuticals, Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Relapsed/Refractory Lymphoma

## Interventions

- **DRUG:** Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection

## Key facts

- **NCT ID:** NCT05189093
- **Lead sponsor:** Hangzhou Hanx Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-31
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05189093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05189093, "Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05189093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*